MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 6, 2008; DOI: 10.1124/mol.107.043182


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043182v1
73/6/1622    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinet, C.
Right arrow Articles by Coulombe, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinet, C.
Right arrow Articles by Coulombe, A.


Received for publication November 5, 2007.
Revised March 5, 2008.
Accepted for publication March 6, 2008.

Protease-Activated Receptor-1 Mediates Thrombin-Induced Persistent Sodium Current in Human Cardiomyocytes

Caroline Pinet 1, Vincent Algalarrondo 2, Sylvie Sablayrolles 3, Bruno Le Grand 3, Christophe Pignier 3, Didier Cussac 3, Michel Perez 3, Stephane N. Hatem 2, Alain Coulombe 4*

1 CNRS, Unite 8162, Le Plessis-Robinson, 92350 France 2 INSERM, Unite 621, Paris, 75013 France 3 Division of Cardiovascular Diseases II, Centre de Recherche Pierre Fabre, Castres, 81106 France 4 University Pierre & Marie Curie

* Address correspondence to: E-mail: alain.coulombe{at}chups.jussieu.fr

Abstract

Following the thrombus formation in cardiac cavities or coronaries, the serine protease thrombin is produced and can therefore reach the myocardial tissue by the active process of extravasation and binds to the G protein-coupled protease-activated receptor-1 (PAR1) expressed in human myocardium. The role of PAR1 was investigated in the thrombin effect on sodium current (INa). INa was recorded in freshly isolated human atrial myocytes by the whole-cell patch-clamp method. Action potentials (AP) were recorded in guinea pig ventricular tissue by the conventional glass microelectrodes technique. Thrombin-activated PAR1 induced a tetrodotoxin-blocked persistent sodium current, INaP, in a concentration-dependent manner with an apparent EC50 of 28 U/ml. The PAR1 agonist peptide SFLLR-NH2 (50 µM) was able to mimic PAR1-thrombin action, whereas PAR1 antagonists, SCH 203099 (10 µM) and ER 112787 (1 µM), completely inhibited it. The activated-PAR1 involves calcium-independent phospholipase-A2 signaling pathway since two inhibitors of this cascade, bromoenol lactone (50 µM) and haloenol lactone suicide substrate (50 µM), block PAR1-thrombin-induced INaP. As a consequence of INaP activation, in guinea pig right ventricle papillary muscle, action potential duration (APD) were significantly increased by 20% and 15% under the respective action of 32 U/ml thrombin and 50 µM SFLLR-NH2, and these increases in APD were prevented by 1 µM TTX or markedly reduced by application of 1 µM SCH 203099 or ER 112787. Thrombin, through PAR1 activation, increases persistent component of the Na current resulting in an uncontrolled sodium influx into the cardiomyocyte which can contribute to cellular injuries observed during cardiac ischemia.


Key words: Thrombin/PAR, Sodium, Gs family, Phospholipase A2's, Ischemia/Reperfusion





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics